According to the terms of the recently announced Biomet hip replacement settlement, the settlement will not be funded until certain pre-conditions are met.
New York, NY (PRWEB) April 26, 2014
As Biomet hip lawsuits involving the M2a Magnum Hip Replacement System (http://www.consumerinjurylawyers.com/biomet-magnum-hip-replacement) continue to mount in federal court, Bernstein Liebhard LLP notes that Zimmer Holdings, Inc. has agreed to buy Biomet, Inc., the manufacturer of the metal-on-metal hip device. According to a report from Fox Business, the sale has already been approved by the boards of both companies, and is expected to be completed by the end of the year.*
“Our Firm is representing numerous clients in lawsuits involving the Biomet M2a Magnum hip. According to the terms of the recently announced Biomet hip replacement settlement, the settlement will not be funded until certain preconditions are met. At the moment, it is unclear whether these preconditions will be met before the expected close of the merger transaction,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free and confidential legal consultations to individuals who may have been injured by metal-on-metal hip implants, including the Biomet M2a Magnum Hip Replacement System.
Biomet Hip Replacement Settlement
The Biomet M2a Magnum hip system is a metal-on-metal hip implant in which the acetabular ball and femoral cup is composed of a chromium/cobalt alloy. In January 2013, the U.S. Food & Drug Administration (FDA) warned that these types of artificial hips may be more likely to fail prematurely compared to devices made from other materials. The agency has advised patients fitted with all-metal hip implants to undergo metal ion blood testing if they experience pain, swelling, or other symptoms that could be an indication that their hip is failing.
According to court documents, more than 1,600 Biomet hip lawsuits have been filed in the U.S. District Court, Northern District of Indiana, on behalf of individuals who allegedly suffered metallosis, pseudotumor formation, chronic pain, and other complications due to its metal-on-metal design. On February 3, 2014, the Court granted approval to a proposed Biomet hip settlement agreement, which if finalized would resolve hundreds of claims involving the device. Under the terms of the settlement, plaintiffs who received one of the affected Biomet hip replacements as part of an initial surgery that was revised more than 180 days after it was implanted would eligible for a base award of $200,000. In order to take effect, court papers indicate that the Biomet hip settlement must be accepted by 90% of eligible plaintiffs. (In re: Biomet M2a Magnum Hip Implant Products Liability Litigation – MDL No. 2391)
Recipients of the Biomet M2a hip implant may be entitled to compensation if they experience complications allegedly related to its all-metal design. Find out more about the litigation involving Biomet hip replacements and other metal-on-metal hip implants by visiting Bernstein Liebhard LLP’s website. To arrange for a free case review, call 800-511-5092 to speak with a member of our legal staff.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
*foxbusiness.com/industries/2014/04/24/zimmer-to-buy-biomet-in-1335-bln-deal/, Fox Business, April 24, 2014
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com